Prodesse, Inc. ProParaflu Assay 510(k) Submission

Page 1 of 7   
Date: November 5, 2009

# Attachment D 510(k) SUMMARY

# CONTACT

Karen Harrington Gen-Probe Prodesse, Inc. W229 N1870 Westwood Dr. Waukesha, WI 53186

# NAME OF DEVICE

Trade Name: Regulation Number: Classification Name:

ProParaflu+TM Assay   
21 CFR 866.3980   
Respiratory viral panel multiplex nucleic acid assay

PREDICATE DEVICE K063765 - ID Tag Respiratory Virus Panel, Luminex Molecular Diagnostics

# INTENDED USE

The ProParaflu+ Assay is a multiplex Real Time RT-PCR in vitro diagnostic test for the qualitative detection and discrimination of Parainfluenza 1 Virus, Parainfluenza 2 Virus and Parainfluenza 3 Virus (HPIV-1, HPIV-2 and HPIV-3) nucleic acids isolated and purified from nasopharyngeal (NP) swab specimens obtained from individuals exhibiting signs and symptoms of respiratory tract infections. This assay targets the conserved regions of the HemagglutininNeuraminidase (HN) gene of HPIV-1, HPIV-2 and HPIV-3, respectively. The detection and discrimination of HPIV-1, HPIV-2 and HPIV-3 nucleic acids from symptomatic patients aid in the diagnosis of human respiratory tract parainfluenza infections if used in conjunction with other clinical and laboratory findings. This test is not intended to detect Parainfluenza 4a or Parainfluenza 4b Viruses.

Negative test results are presumptive and should be confirmed by cell culture. Negative results do not preclude Parainfluenza 1, 2 or 3 virus infections and should not be used as the sole basis for treatment or other management decisions.

# PRODUCT DESCRIPTION

The ProParaflu+ Assay enables the detection and differentiation of Parainfluenza I Virus, Parainfluenza 2 Virus, Parainfluenza 3 Virus and an Internal Control (IC) nucleic acid. Nasopharyngeal swab specimens from symptomatic patients using a polyester, rayon or nylon tipped swab and place into viral transport medium. The IC is added to every sample prior to nucleic acid extraction to monitor for inhibitors present in the specimens.

Isolation and purification of nucleic acids is performed using the bioMérieux NucliSENS easyMAG automated extractor and the Automated Magnetic Extraction Reagents or the Roche MagNA Pure LC Instrument and the MagNA Pure Total Nucleic Acid Isolation Kit.

The purified nucleic acids are added to the ProParaflu $+$ Supermix along with enzymes included in the ProParaflu+ Detection Kit. The ProParaflu+ Supermix contains oligonucleotide primers that are complementary to highly conserved regions of hemagglutinin neuraminidase gene for each human Parainfluenza type (1, 2 and 3). The probes are dual-labeled with a reporter dye attached to the $5 ^ { \circ }$ -end and a quencher dye attached to the $_ { 3 } ,$ -end (see table below).

RT-PCR amplification is performed in a Cepheid SmartCycler ${ \mathfrak { G } } _ { \mathrm { I I } }$ instrument. During this process, the primers and probes anneal specifically to the template (if present) followed by primer extension and amplification. The ProParaflu+ Assay is based on Taqman chemistry, which utilizes the $5 ' - 3 '$ exonuclease activity of the Taq polymerase to cleave the probe thus separating the reporter dye from the quencher. This generates an increase in fluorescent signal upon excitation from a light source. With each cycle, additional reporter dye molecules are cleaved from their respective probes, further increasing the fluorescent signal. The amount of fluorescence at any given cycle is dependent on the amount of amplification product present at that time. Fluorescent intensity is monitored during each PCR cycle by the real-time instrument. Results are analyzed and interpreted as presented by the software.

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Gene Targeted</td><td rowspan=1 colspan=1>ProbeFluorophore</td><td rowspan=1 colspan=1>AbsorbancePeak</td><td rowspan=1 colspan=1>EmissionPeak</td><td rowspan=1 colspan=1>InstrumentChannel</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 1Virus</td><td rowspan=1 colspan=1>Hemagglutininneuraminidase</td><td rowspan=1 colspan=1>FAM</td><td rowspan=1 colspan=1>495 nm</td><td rowspan=1 colspan=1>520 nm</td><td rowspan=1 colspan=1>FAM</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 3Virus</td><td rowspan=1 colspan=1>Hemagglutininneuraminidase</td><td rowspan=1 colspan=1>Cal Orange 560</td><td rowspan=1 colspan=1>540 nm</td><td rowspan=1 colspan=1>561 nm</td><td rowspan=1 colspan=1>TET</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 2Virus</td><td rowspan=1 colspan=1>Hemagglutininneuraminidase</td><td rowspan=1 colspan=1>Cal Red 610</td><td rowspan=1 colspan=1>595 nm</td><td rowspan=1 colspan=1>615 nm</td><td rowspan=1 colspan=1>Texas Red</td></tr><tr><td rowspan=1 colspan=1>Internal Control</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>Quasar 670</td><td rowspan=1 colspan=1>647 nm</td><td rowspan=1 colspan=1>667 nm</td><td rowspan=1 colspan=1>$Cy_\}$</td></tr></table>

# SUBSTANTIAL EQUIVALENCE

Clinical Performance

The clinical performance of the ProParaflu $+$ Assay was established during a prospective study at 4 U.S. clinical laboratories during May 2008  September 2009. Specimens used in the study represented excess nasopharyngeal (NP) swab specimens that were prospectively collected from symptomatic individuals suspected of respiratory infection, and were submitted for routine analysis. Demographic details for this patient population are summarized in the following table.

Gender and Age Demographic Detail for ProParaflu+ Prospective Study   

<table><tr><td rowspan=1 colspan=1>Sex</td><td rowspan=1 colspan=1>Number of Subjects</td></tr><tr><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>407 (47.5%)</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>450 (52.5%)</td></tr><tr><td rowspan=1 colspan=1>Age (yrs)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>580 (67.7%)</td></tr><tr><td rowspan=1 colspan=1>6 - 21 years</td><td rowspan=1 colspan=1>168 (19.6%)</td></tr><tr><td rowspan=1 colspan=1>22-59 years</td><td rowspan=1 colspan=1>67 (7.8%)</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>42 (4.9%)</td></tr></table>

Performance of the ProParaflu+ Assay was compared to the reference method of cell culture (rapid or traditional) followed by direct fluorescent antibody (DFA) screening and HPIV type identification.

A total of 857 eligible NP swab samples were tested with the ProParaflu+ Assay and by culture across four clinical sites. Of the ProParaflu+ Assay run on all eligible specimens, $9 9 . 2 \%$ EY (852/857) of these specimens were successful on the first attempt. The remaining 5 gave Unresolved" results on the first attempt. Unresolved results occur when the sample is negative for all three HPIVs and the Internal Control, indicating potentially PCR-inhibiting samples. Of the 5 "Unresolved" specimens on the first attempt, $6 0 . 0 \%$ (3/5) gave a valid result on the second attempt. The remaining 2 were "Unresolved" on the second attempt and are not included in the analysis below. Both samples were culture negative.

Discrepant analysis for samples where ProParaflu $^ +$ Assay and culture results were in disagreement was performed using RT-PCR with virus specific primers obtained from literature8 9 (and different from those used in ProParaflu+) followed by bi-directional sequencing.

# Prospective Study

# Parainfluenza 1 Comparison Results

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Prorwssy</td><td rowspan=2 colspan=1>PositiveNegative</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>Sensitivity 88.9% (67.2% - 96.9%)95% CI</td></tr><tr><td rowspan=1 colspan=1>2b</td><td rowspan=1 colspan=1>838.</td><td rowspan=1 colspan=1>840</td><td rowspan=1 colspan=1>Specificity 99.9% (99.3% -100.0%) 95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1> Total</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>839</td><td rowspan=1 colspan=1>857</td><td rowspan=1 colspan=1></td></tr></table>

One (1) sample positive for HPIV-1 by bi-directional sequence analysis. aiv  al  nalysOepl v for HPIV-3 by ProParaflu+ and bi-directional sequence analysis.

# Parainfluenza 2 Comparison Results

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2>EY</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative Total</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Prorssy</td><td rowspan=2 colspan=1>PositiveNegative</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>2a</td><td rowspan=1 colspan=1>28“</td><td rowspan=1 colspan=1>Sensitivity 96.3% (81.7% - 99.3%)95% CI</td></tr><tr><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>828</td><td rowspan=1 colspan=1>829</td><td rowspan=1 colspan=1>Specificity 99.8% (99.1% - 99.9%)95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>830</td><td rowspan=1 colspan=1>857</td><td rowspan=1 colspan=1></td></tr></table>

Two (2) samples positive for HPIV-2 by bi-directional sequence analysis. bOne (1) sample negative for HPIV-2 by bi-directional sequence analysis.

# Parainfluenza 3 Comparison Results

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative Total</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Proornwssy</td><td rowspan=2 colspan=1>PositiveNegative</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>ga</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>Sensitivity 97.3% (86.2% - 99.5%)95% CI</td></tr><tr><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>812</td><td rowspan=1 colspan=1>813</td><td rowspan=1 colspan=1>Specificity 99.2% (98.1% - 99.5%)95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>820</td><td rowspan=1 colspan=1>857</td><td rowspan=1 colspan=1></td></tr></table>

Seven (7) samples positive for HPIV-3 and one (1) sample negative for HPIV-3 by bidirectional sequence analysis. bOne (1) sample negative for HPIV-3 by bi-directional sequence analysis.

# Retrospective Study

Due to a minimal number of HPIV-1 positive samples, a retrospective study was also conducted using a total of 91 frozen NP swab samples that had been previously tested by direct DFA. Demographic details for this patient population are summarized in the following table.

Gender and Age Demographic Detail for ProParaflu $^ +$ Retrospective Study   

<table><tr><td rowspan=1 colspan=1>Sex                                     J</td><td rowspan=1 colspan=1>Number of Subjects</td></tr><tr><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>40 (44.4%)</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>50 (55.6%)</td></tr><tr><td rowspan=1 colspan=1>Age (yrs)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>81 (90.0%)</td></tr><tr><td rowspan=1 colspan=1>6-21 years</td><td rowspan=1 colspan=1>5 (5.6%)</td></tr><tr><td rowspan=1 colspan=1>22- 59 years</td><td rowspan=1 colspan=1>2 (2.2%)</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>2 (2.2%)</td></tr></table>

# Parainfluenza 1 Comparison Results

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>DFA</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative Total</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Prorssy</td><td rowspan=2 colspan=1>PositiveNegative</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>Sensitivity 82.8% (65.4% - 92.4%)95% CI</td></tr><tr><td rowspan=1 colspan=1>5a</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>Specificity 100% (94.2% - 100%)95% CI</td></tr><tr><td rowspan=1 colspan=1>——</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1></td></tr></table>

Five (5) samples negative for HPIV-1 by bi-directional sequence analysis.

# Reproducibility

The reproducibility of the ProParafl $u +$ Assay was evaluated at 3 laboratory sites. Reproducibility was assessed using a panel of 12 simulated samples that included medium positive, low positive (near the assay limit of detection, $2 9 5 \%$ positive), intermediate (1 log below the assay limit of detection), and high negative (below the assay limit of detection, ${ < } 5 \%$ positive) samples. Panels and controls were tested at each site by 2 operators for 5 days. The overall percent agreement with the expected result for the ProParaflu $^ { 1 + }$ Assay was $9 7 . 8 \%$ .

<table><tr><td rowspan=3 colspan=1></td><td rowspan=2 colspan=1>Panel MemberD</td><td rowspan=2 colspan=1>e  1AldH</td><td rowspan=2 colspan=1>Jod Mo PAdH</td><td rowspan=2 colspan=1>PotidImpae 1-Adn</td><td rowspan=2 colspan=1>had h20</td><td rowspan=2 colspan=1>JAd M Z-AldH</td><td rowspan=2 colspan=1>pamIZAdH</td><td rowspan=2 colspan=1>IE-AII</td><td rowspan=2 colspan=1>Hsod Mo EAdH</td><td rowspan=2 colspan=1>Jad n -AdH</td><td rowspan=2 colspan=1>Cea o a</td><td rowspan=2 colspan=3>Para RNA ControlPAIdH     ZAIH     3i.</td><td rowspan=2 colspan=1>N it</td><td rowspan=2 colspan=1>Jo % </td></tr><tr><td rowspan=1 colspan=1>ZAIH</td></tr><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>0.001XLoD</td><td rowspan=1 colspan=1>2XLoD</td><td rowspan=1 colspan=1>10XLoD</td><td rowspan=1 colspan=1>0.001 xLoD</td><td rowspan=1 colspan=1>2XLoD</td><td rowspan=1 colspan=1>10XLOD</td><td rowspan=1 colspan=1>0.01 XLoD</td><td rowspan=1 colspan=1>2XLoD</td><td rowspan=1 colspan=1>10XLoD</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=3>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=9 colspan=1>SiteSite2Site3</td><td rowspan=1 colspan=1>Agreement withExpected Result</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>8/1080%</td><td rowspan=1 colspan=1>9/9100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>9/9100%</td><td rowspan=1 colspan=1>9/1090%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>9/1090%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>114/11896.6%</td></tr><tr><td rowspan=1 colspan=1>Mean Ct Value</td><td rowspan=1 colspan=1>27.73</td><td rowspan=1 colspan=1>28.31</td><td rowspan=1 colspan=1>26.33</td><td rowspan=1 colspan=1>27.90</td><td rowspan=1 colspan=1>28.62</td><td rowspan=1 colspan=1>26.27</td><td rowspan=1 colspan=1>27.76</td><td rowspan=1 colspan=1>31.21</td><td rowspan=1 colspan=1>29.47</td><td rowspan=1 colspan=1>27.33</td><td rowspan=1 colspan=1>27.37</td><td rowspan=1 colspan=1>29.37</td><td rowspan=1 colspan=1>28.61</td><td rowspan=1 colspan=1>27.69</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>2.84</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>2.43</td><td rowspan=1 colspan=1>3.21</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>1.67</td></tr><tr><td rowspan=1 colspan=1>Agreement withExpected Result</td><td rowspan=1 colspan=1>8/1080%</td><td rowspan=1 colspan=1>8/1080%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>116/12096.7%</td></tr><tr><td rowspan=1 colspan=1>Mean Ct Value</td><td rowspan=1 colspan=1>28.59</td><td rowspan=1 colspan=1>28.47</td><td rowspan=1 colspan=1>26.12</td><td rowspan=1 colspan=1>28.83</td><td rowspan=1 colspan=1>28.91</td><td rowspan=1 colspan=1>26.61</td><td rowspan=1 colspan=1>28.30</td><td rowspan=1 colspan=1>31.64</td><td rowspan=1 colspan=1>29.51</td><td rowspan=1 colspan=1>27.56</td><td rowspan=1 colspan=1>23.86</td><td rowspan=1 colspan=1>26.09</td><td rowspan=1 colspan=1>25.23</td><td rowspan=1 colspan=1>28.68</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>2.80</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>2.17</td><td rowspan=1 colspan=1>2.66</td><td rowspan=1 colspan=1>2.47</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.15</td></tr><tr><td rowspan=1 colspan=1>Agreement withExpected Result</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>120/120100%</td></tr><tr><td rowspan=1 colspan=1>Mean Ct Value</td><td rowspan=1 colspan=1>26.35</td><td rowspan=1 colspan=1>29.91</td><td rowspan=1 colspan=1>27.67</td><td rowspan=1 colspan=1>26.28</td><td rowspan=1 colspan=1>29.51</td><td rowspan=1 colspan=1>27.44</td><td rowspan=1 colspan=1>26.67</td><td rowspan=1 colspan=1>33.13</td><td rowspan=1 colspan=1>30.43</td><td rowspan=1 colspan=1>28.61</td><td rowspan=1 colspan=1>28.73</td><td rowspan=1 colspan=1>30.98</td><td rowspan=1 colspan=1>29.84</td><td rowspan=1 colspan=1>26.46</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>2.25</td><td rowspan=1 colspan=1>4.13</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>1.54</td><td rowspan=1 colspan=1>3.31</td><td rowspan=1 colspan=1>3.39</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>1.04</td></tr><tr><td rowspan=4 colspan=1></td><td rowspan=1 colspan=1>Total Agreementwith ExpectedResult</td><td rowspan=1 colspan=1>28/3093.3%</td><td rowspan=1 colspan=1>26/3086.7%</td><td rowspan=1 colspan=1>29/29100%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=1>29/29100%</td><td rowspan=1 colspan=1>29/3096.7%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=1>29/3096.7%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=3>30/30100%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=1>350/35897.8%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>78.7%-98.2%</td><td rowspan=1 colspan=1>70.3%-94.7%</td><td rowspan=1 colspan=1>88.3%-100%</td><td rowspan=1 colspan=1>88.6%-100%</td><td rowspan=1 colspan=1>88.3%-100%</td><td rowspan=1 colspan=1>83.3%-99.4%</td><td rowspan=1 colspan=1>88.6%-100%</td><td rowspan=1 colspan=1>83.3%99.4%</td><td rowspan=1 colspan=1>88.6%-100%</td><td rowspan=1 colspan=1>88.6%100%</td><td rowspan=1 colspan=3>88.6% - 100%</td><td rowspan=1 colspan=1>88.6%-100%</td><td rowspan=1 colspan=1>95.6%-98.9%</td></tr><tr><td rowspan=1 colspan=1>Overall Mean CtValue</td><td rowspan=1 colspan=1>27.56</td><td rowspan=1 colspan=1>28.90</td><td rowspan=1 colspan=1>26.72</td><td rowspan=1 colspan=1>27.67</td><td rowspan=1 colspan=1>29.03</td><td rowspan=1 colspan=1>26.79</td><td rowspan=1 colspan=1>27.58</td><td rowspan=1 colspan=1>32.02</td><td rowspan=1 colspan=1>29.80</td><td rowspan=1 colspan=1>27.83</td><td rowspan=1 colspan=1>26.65</td><td rowspan=1 colspan=1>28.81</td><td rowspan=1 colspan=1>27.89</td><td rowspan=1 colspan=1>27.62</td><td rowspan=2 colspan=1>→</td></tr><tr><td rowspan=1 colspan=1>Overall% CV</td><td rowspan=1 colspan=1>3.88</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>4.55</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>3.68</td><td rowspan=1 colspan=1>3.61</td><td rowspan=1 colspan=1>2.42</td><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>8.13</td><td rowspan=1 colspan=1>7.49</td><td rowspan=1 colspan=1>7.39</td><td rowspan=1 colspan=1>3.54</td></tr></table>

"Average Ct value for the Internal Control (IC)

An additional reproducibility study was performed to assess samples that were at an intermediate concentration, below the assay's LoD but above the "high negatives" tested during the original reproducibility study. The percent positive for the intermediate member across all sites was $5 6 . 7 \%$ for HPIV-1 (mean $\mathrm { C t } = 3 5 . 1 $ ), $8 6 . 7 \%$ for HPIV-2 (mean $\mathrm { C t } = 3 3 . 0 )$ , and $3 0 . 0 \%$ for HPIV-3 (mean $\mathrm { C t } = 3 7 . 1 $ ). This result was expected as the intermediate concentration should be positive in the range of $5 - 9 5 \%$ as the samples were lower concentration than the LoD concentration $( \geq 9 5 \%$ positive) and higher than the "high negative" concentration $( < 5 \%$ positive).

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>Panel Member ID</td><td rowspan=1 colspan=1>Hre re</td><td rowspan=1 colspan=1>Hme tr</td><td rowspan=1 colspan=1>tittiee3AIdH</td><td rowspan=1 colspan=1>Ctuncor</td><td rowspan=1 colspan=4>Parainfluenza RNA     Ne ControlI-AldHZ-AIdHE-AIdH</td></tr><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>0.1 X LoD</td><td rowspan=1 colspan=1>0.1 X LoD</td><td rowspan=1 colspan=1>0.1 X LoD</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=3>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=3 colspan=1>Site I</td><td rowspan=1 colspan=1>Agreement with PositiveResult</td><td rowspan=1 colspan=1>4/1040%</td><td rowspan=1 colspan=1>8/10.80%</td><td rowspan=1 colspan=1>1/1010%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10*100%</td></tr><tr><td rowspan=1 colspan=1>Average Ct Value</td><td rowspan=1 colspan=1>35.5</td><td rowspan=1 colspan=1>33.3</td><td rowspan=1 colspan=1>36.9</td><td rowspan=1 colspan=1>27.9</td><td rowspan=1 colspan=1>28.8</td><td rowspan=1 colspan=1>30.4</td><td rowspan=1 colspan=1>29.5</td><td rowspan=1 colspan=1>28.4</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>6.19</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>3.80</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>3.47</td></tr><tr><td rowspan=6 colspan=1>Site 2Site 3</td><td rowspan=1 colspan=1>Agreement with Positiveesult</td><td rowspan=1 colspan=1>8/1080%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=1>7/1070%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td></tr><tr><td rowspan=1 colspan=1>Average Ct Value</td><td rowspan=1 colspan=1>34.4</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>37.3</td><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>30.6</td><td rowspan=1 colspan=1>29.9</td><td rowspan=1 colspan=1>27.7</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>2.92</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>2.80</td></tr><tr><td rowspan=1 colspan=1>Agreement with PositiveResult</td><td rowspan=1 colspan=1>5/1050%</td><td rowspan=1 colspan=1>8/1080%</td><td rowspan=1 colspan=1>1/1010%</td><td rowspan=1 colspan=1>10/10100%</td><td rowspan=1 colspan=3>10/10100%</td><td rowspan=1 colspan=1>10/10100%</td></tr><tr><td rowspan=1 colspan=1>Average Ct Value</td><td rowspan=1 colspan=1>35.9</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>35.8</td><td rowspan=1 colspan=1>28.6</td><td rowspan=1 colspan=1>29.7</td><td rowspan=1 colspan=1>31.5</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>27.9</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>2.44</td><td rowspan=1 colspan=1>2.90</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>1.69</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>1.94</td></tr><tr><td rowspan=4 colspan=1></td><td rowspan=1 colspan=1>Total Agreement withPositive Result</td><td rowspan=1 colspan=1>17/3056.7%</td><td rowspan=1 colspan=1>26/3086.7%</td><td rowspan=1 colspan=1>9/3030.0%</td><td rowspan=1 colspan=1>30/30100%</td><td rowspan=1 colspan=3>30/30100%</td><td rowspan=1 colspan=1>30/30100%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>39.2%-72.6%</td><td rowspan=1 colspan=1>70.3%-94.7%</td><td rowspan=1 colspan=1>16.7%-47.9%</td><td rowspan=1 colspan=1>88.7-100%</td><td rowspan=1 colspan=3>88.7 - 100%</td><td rowspan=1 colspan=1>88.7-100%</td></tr><tr><td rowspan=1 colspan=1>Overall Average Ct Value</td><td rowspan=1 colspan=1>35.1</td><td rowspan=1 colspan=1>33.0</td><td rowspan=1 colspan=1>37.1</td><td rowspan=1 colspan=1>28.0</td><td rowspan=1 colspan=1>29.1</td><td rowspan=1 colspan=1>30.8</td><td rowspan=1 colspan=1>29.9</td><td rowspan=1 colspan=1>28.0</td></tr><tr><td rowspan=1 colspan=1>Overall % CV</td><td rowspan=1 colspan=1>3.68</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>1.89</td><td rowspan=1 colspan=1>3.46</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>2.92</td></tr></table>

Average Ct value for the Internal Control (IC) \*Agreement with Negative result

Dr. Karen Harrington Manager, Clinical Affairs Prodesse Inc. W229 N1870 Westwood Drive Waukesha, WI 53186

# NOV 2 0 2009

Re: K091053 Trade/Device Name: ProParaflu $^ +$ TM Assay Regulation Number: 21 CFR 866.3980 Regulation Name: Respiratory viral panel multiplex nucleic acid assay Regulatory Class: Class II Product Code: OOU Dated: October 14, 2009 Received: October 15, 2009

Dear Dr. Harrington:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as sel forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/d0fb0c87192085bca4a7c2349fd5d4f4770ab0221f46b69e85591c55df23fa77.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use

510(k) Number (if known): k091053

Device Name: ProParaflu $\mathbf { \alpha } _ { \mathrm { i + T M } }$ Assay

Indication For Use:

The ProParaflu+ Assay is a multiplex Real Time RT-PCR in vitro diagnostic test for the qualitative detection and discrimination of Parainfluenza 1 Virus, Parainfluenza 2 Virus and Parainfluenza 3 Virus (HPIV-1, HPIV-2 and HPIV-3) nucleic acids isolated and purified from nasopharyngeal (NP) swab specimens obtained from individuals exhibiting signs and symptoms of respiratory tract infections. This assay targets the conserved regions of the Hemagglutinin-Neuraminidase (HN) gene of HPIV-1, HPIV-2 and HPIV3, respectively. The detection and discrimination of HPIV-1, HPIV-2 and HPIV-3 nucleic acids from symptomatic patients aid in the diagnosis of human respiratory tract parainfluenza infections if used in conjunction with other clinical and laboratory findings. This test is not intended to detect Parainfluenza 4a or Parainfluenza 4b Viruses.

Negative test results are presumptive and should be confirmed by cell culture. Negative results do not preclude Parainfluenza 1, 2 or 3 virus infections and should not be used as the sole basis for treatment or other management decisions.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

M Sf

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety